title: Simplified pepstatins: synthesis and evaluation of N-terminally modified analogues.
abstract: The promising strategy of gastric ulcer healing with perorally administered epidermal growth factor (EGF) is so far strongly limited by the pepsinic degradation of this therapeutic polypeptide in the stomach. The incorporation of EGF in a bioadhesive polymer-pepsin inhibitor conjugate used as drug carrier matrix, however, might provide sufficient protection toward pepsinic degradation. The synthesis of appropriate pepsin inhibitors represents a prerequisite for the development of such polymer-inhibitor conjugates. The presented study demonstrates that modifications at the N-terminus of simplified analogues of pepstatin which can be synthesized in a simple and straight way result only in slight variations of the inhibitory activity. These analogues display only 10-fold reduced inhibitory activity, compared to pepstatin A, when bearing a greater N-terminal group like isovaleryl, Boc, or Cbz. Compounds which are substituted at the N-terminus by a shorter N-acyl group like propionyl or cyclopropylcarbonyl show further reduced activity (0.01, compared to pepstatin A). The presence of an amide or a urethane moiety at the N-terminus has no considerable effect on enzyme inhibition. Therefore, the N-terminus of these analogues is able to be modified forming a covalent bond to various bioadhesive polymers via a suitable functionality.
authors.affiliation: Institute of Pharmaceutical Chemistry and Institute of Pharmaceutical Technology, Center of Pharmacy, Althanstrasse 14, A-1090 Vienna, Austria.
authors.forename: M
authors.initials: M
authors.lastname: Kratzel
authors.forename: B
authors.initials: B
authors.lastname: Schlichtner
authors.forename: R
authors.initials: R
authors.lastname: Kirchmayer
authors.forename: A
authors.initials: A
authors.lastname: Bernkop-Schnürch
mesh_terms: D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D016503:Drug Delivery Systems; D004815:Epidermal Growth Factor / Q000008:administration & dosage; D010436:Pepstatins / Q000138:chemical synthesis* / Q000737:chemistry; D011480:Protease Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry
chemical_list: D000897:Anti-Ulcer Agents; D010436:Pepstatins; D011480:Protease Inhibitors; C014195:Streptomyces pepsin inhibitor; D004815:Epidermal Growth Factor; C031375:pepstatin